Perfusion Systems Market Analysis 2018-2027: Merck, Ala Scientific Instruments, XVIVO Perfusion, Medtronic, XENIOS, TERUMO CORPORATION, Getinge, Harvard Bioscience, and OrganOx

The global perfusion systems market accounted to US$ 1,044.75 Mn in 2018 and is expected to grow at a CAGR of 3.8% during the forecast period 2019 - 2027, to account to US$ 1,442.28 Mn by 2027.

Key factors driving the market are rising prevalence of cardiovascular diseases, significant growth of pharmaceutical and biotechnology industries, rising need for the organ transplantation, and rising cell based research activities. However, factors such as expensive organ transplant surgeries, and limited numbers of donors for organ transplant surgeries are likely to restrain the market growth to a certain extent.

Get sample PDF copy: http://bit.ly/2WH8LkC

The prominent players operating in perfusion systems market are REPLIGEN CORPORATION, Merck KGaA, Ala Scientific Instruments, Inc., XVIVO Perfusion, Medtronic, XENIOS AG (Fresenius Medical Care AG & Co. KGaA), Getinge AB, TERUMO CORPORATION, LivaNova PLC, Sartorius AG, Harvard Bioscience, RAND, Sanisure (Sani-Tech West, Inc.), AutoMate Scientific, Inc., Jobst Technologies GmbH, APD (Advanced Perfusion Diagnostics), Spectrum Medical, Transonic Systems Inc, OrganOx, ISCHEMAVIEW, INC, and CESCO BIOENGINEERING CO., LTD.

The market players are focused towards bringing new and innovative products to sustain their position in the market. For instance, in March 2018, Sartorius Stedim Biotech (Sartorius AG) launched ambr 250 high throughput (ht) perfusion, specially designed for rapid cell culture perfusion process development to optimize production of therapeutic antibodies. The developments performed by the companies are helping the market to grow in the coming years.

The perfusion systems market by type is segmented into bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure driven perfusion systems, and small mammal organ perfusion systems. In 2018, the bioreactor perfusion systems segment held a largest market share of 44.3% of the perfusion systems market, by type. This segment is also expected to dominate the market in 2027 owing to increasing production by the biopharmaceutical and pharmaceutical and its advantages including, high quality of product, product stability, and scalability. Moreover, the microfluidic perfusion systems segment is anticipated to witness the significant growth rate of 3.9% during the forecast period, 2019 to 2027 owing to increasing application of basic cell biology, molecular biological assays, tissue engineering, and systems biology.

Buy the complete report @ http://bit.ly/2WE3TwF

Strategic Insights

Strategic acquisition and product launches were observed as the most adopted strategy in global perfusion systems industry. Few of the recent product launch, product approval and acquisitions are listed below:

2018: XVIVO Perfusion has submitted the Premarket Approval (PMA) application for the XPS with STEEN Solution to the FDA.

2019: Sartorius Stedim Biotech (Sartorius AG) launched ambr 250 high throughput (ht) perfusion, specially designed for rapid cell culture perfusion process development to optimize production of therapeutic antibodies.

2018: Spectrum Medical announced acquisition of the second exclusive licensing agreement with the University of California, Los Angeles (UCLA) Technology Development Group on behalf of UC Regents. The license is in association of the intellectual property that supports clinical applications requiring Extracorporeal Circulation.

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
Web: https://www.theinsightpartners.com/

This release was published on openPR.